Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
The role of cytoreductive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas Hodul P; Malafa M; Choi J; Kvols LCancer Control 2006[Jan]; 13 (1): 61-71BACKGROUND: Patients with metastatic neuroendocrine cancers to the liver often present with disabling endocrinopathies and pain associated with bulky disease. Quality of life for these patients is poor and can require long-term therapy with somatostatin analogs for control of their symptoms. Alternative therapies to decrease tumor burden and subsequent hormone release have been investigated. Of these, cytoreductive surgery was found to have the most consistent and profound impact on symptom regression and overall survival. METHODS: Several cases are reported that illustrate an aggressive multimodality approach in the treatment of metastatic neuroendocrine cancers to the liver. The literature is reviewed and the role of cytoreductive surgery in the management of hepatic neuroendocrine metastases is discussed. RESULTS: Cytoreductive surgery can be performed safely with minimal morbidity and mortality. Regression of symptoms occurs in the majority of patients and survival is prolonged. CONCLUSIONS: Surgical intervention as part of an aggressive multimodality treatment plan results in improved outcomes for patients with advanced hepatic metastases of neuroendocrine origin. Future directions may include earlier surgical intervention with adjuvant therapies reserved for aggressive recurrent disease.|Adult[MESH]|Aged, 80 and over[MESH]|Antineoplastic Agents/therapeutic use[MESH]|Catheter Ablation[MESH]|Combined Modality Therapy[MESH]|Embolization, Therapeutic[MESH]|Female[MESH]|Hepatic Artery[MESH]|Humans[MESH]|Liver Neoplasms/*secondary/*surgery/therapy[MESH]|Male[MESH]|Malignant Carcinoid Syndrome/*surgery/therapy[MESH]|Middle Aged[MESH]|Neuroendocrine Tumors/*secondary/surgery/therapy[MESH]|Pancreatic Neoplasms/*pathology[MESH]|Treatment Outcome[MESH]|Tumor Burden[MESH] |
